Loading…
← CockpitCompetitor Analysis › 000597.SZ Northeast Pharmaceutical Group Co., Ltd. Class AOpen in the cockpit ↗

Northeast Pharmaceutical Group Co., Ltd. Class A000597.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

State-owned Liaoning antibiotics and amino-acid API maker, one of China's earliest large-scale pharmaceutical manufacturers.

≈ A Chinese state-owned legacy antibiotics/amino-acid makerMomentum strong 62
Mkt cap
$895M
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$6.14M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+2.2 pp
WACC 5.0%
Hurdle
-7 pp
Req g minus delivered
Close · CNYCN¥4.20
1D-0.9%
1W-4.1%
1M-10.3%
3M-15.5%
6M-13.9%
YTD-19.5%
1Y-25.1%
ATR %2.8%
52w lowhigh29.2% off high

What Northeast Pharmaceutical does

State-owned Liaoning antibiotics and amino-acid API maker, one of China's earliest large-scale pharmaceutical manufacturers.

Sells antibiotic and amino-acid ingredients in bulk to formulators and hospitals, so profit depends on global ingredient prices and plant utilisation rather than branding. State ownership gives it scale from the planned-economy era but little pricing power.

In one line: A Chinese state-owned legacy antibiotics/amino-acid maker.

Products and services

  • Antibiotic APIs
  • Amino acid products
  • Finished formulations

Customers

  • Hospitals
  • Generic-drug formulators

Where it sits in the supply chain

  • Pharmaceuticals
  • Active ingredients
  • Antibiotics and amino acids

What could go right

  • Antibiotic/amino-acid export demand

What could go wrong

  • Overcapacity and price competition

Moat: none (scale). Legacy state-owned scale in commodity APIs without a differentiated product line.

Headquarters: Shenyang, China · Founded: 1946 · Employees: 5,727

Named competitors

Northeast Pharmaceutical at a glance

Size Northeast Pharmaceutical (000597.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $895M, the 2374th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.20 on 18 Nov 2026.

Performance Over six months the shares fell 13.9%, against -24.5% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue fell 5.8% over the last twelve months (peer median +13.0%); the operating margin is 2.7% (peer median 7.1%).

Valuation It trades at 0.9× enterprise value to sales against a peer median of 4.3× (2nd cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -7 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.2 points above its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026000597.SZ 87Peer median 77
Six months, rebased to 100: Northeast Pharmaceutical against the median of its 20 peers (local-currency closes).

Northeast Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥6.45BCN¥7.04BCN¥7.47BCN¥8.16BCN¥8.73B
Revenue growth—-6%-9%-6%—
Gross profitCN¥2.59BCN¥2.48BCN¥2.74BCN¥3.14BCN¥3.23B
EBITDAn/aCN¥803MCN¥1.06BCN¥941MCN¥782M
Net incomeCN¥189MCN¥260MCN¥410MCN¥358MCN¥350M
Free cash flowCN¥837MCN¥1.01BCN¥599MCN¥351MCN¥864M
Capital expenditureCN¥82.2MCN¥97.8MCN¥159MCN¥235MCN¥244M
Total debtCN¥4.29BCN¥3.77BCN¥5.54BCN¥6.91BCN¥5.25B

Quarterly statements and history in the cockpit →

Northeast Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%AKTS6885532595IMTXMLTX1795SANOFICONR300401PHARM0392000061206007716881774521069620600252086450000597.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Northeast Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%0×20×40×60×AKTS6885532595IMTX1795SANOFICONR300401PHARM039200000597.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Northeast Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%6885531795SANOFICONR300401PHARM039200600771600252086450000597.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Northeast Pharmaceutical is the large dot.

Northeast Pharmaceutical competitors and peer comparison

Head to head with its named competitors (000597.SZ vs 600812.SS vs 600789.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Northeast Pharmaceutical 000597.SZ$895M-14%-6%3%0.9×-7.6%
North China Pharmaceutical 600812.SS$1.08B-12%-21%5%2.4×1.0%
Shandong Lukang Pharmaceutical 600789.SS$1.05B-18%-7%3%1.5×2.5%

How Northeast Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Northeast Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000597.SZPeer medianRank in peer set
1-month return-10.3%-7.7%10th lowest of 21
6-month return-13.9%-24.5%6th highest of 19
Distance from 52-week high-29.2%-46.6%4th highest of 21
Revenue growth (TTM)-5.8%+13.0%4th lowest of 18
Operating margin2.7%7.1%8th lowest of 18
EV / Sales0.9×4.3×2nd cheapest of 17
Growth the price implies (Req g, 7 yrs)-7.6%9.1%2nd least demanding of 10
Growth delivered (Del g)-0.7%+12.4%3rd lowest of 10
Hurdle (Req g minus delivered)-6.9 pp-4.9 pp5th least demanding of 10
ROIC minus cost of capital+2.2 pp+1.4 pp5th highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%0.9×-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%33.4×n/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%3.5×19.4%-6.0%
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%55.9×n/an/a
Immatics IMTXUnited States$913M-46%-44%-589%8.5×n/an/a
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%2.6×-3.7%+13.8%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%8.3×17.7%+22.7%
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%5.2×9.1%+13.4%
Pharming PHARM.ASNetherlands$867M-6%+2%9%2.2×2.4%+12.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%7.5×-10.2%+18.1%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%0.8×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%4.1×31.7%+4.2%
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%6.5×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%4.5×10.3%-13.7%
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%

Questions

Who are Northeast Pharmaceutical's main competitors?
Named competitors: North China Pharmaceutical (600812.SS), Shandong Lukang Pharmaceutical (600789.SS). The cockpit's measured peer set (industry) also includes Aktis Oncology (AKTS), Sichuan Huiyu Pharmaceutical (688553.SS), Latigo Biotherapeutics (LTGO), Genfleet Therapeutics (Shanghai) (2595.HK), Immatics (IMTX), MoonLake Immunotherapeutics (MLTX).
Is Northeast Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 0.9× against a peer median of 4.3×, 2nd cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -7 pp: the price already allows for a slowdown.
How has Northeast Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -13.9% against -24.5% for the median peer; over one year -25.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.